A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

▤ Summary

Akeso and Summit Therapeutics reported that ivonescimab cut the risk of death by 34% in a late-stage lung cancer trial conducted in China. The drug also extended median survival by about four months when used with chemotherapy in squamous non-small-cell lung cancer. The results strengthen the debate around PD-1/VEGF therapies, but questions remain about how well the China-only data will translate to global patients. Summit still plans to release additional global trial data later this year and next year. The story also highlights continued investor interest and licensing activity around next-generation oncology drugs.

▦ Linked Companies

Roche

$1B+